ArticleAging2011
Progeria, rapamycin and normal aging: recent breakthrough.
Article in Aging, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 50 citations in OpenAlex.
- Exploring the Senotherapeutic Potential of Polyphenols in Aging and Disease: A Literature Review.International journal of molecular sciences · 2026Review
- Rapamycin Rescues Age-Related Changes in Muscle-Derived Stem/Progenitor Cells from Progeroid Mice.Molecular therapy. Methods & clinical development · 2019Article
- High Body Mass Index is Associated with Elevated Blood Levels of Progerin mRNA.International journal of molecular sciences · 2019Article
- HIF1α-mediated AIMP3 suppression delays stem cell aging via the induction of autophagy.Aging cell · 2019Article
- Rapamycin‑induced miR‑30a downregulation inhibits senescence of VSMCs by targeting Beclin1.International journal of molecular medicine · 2019Article
- Regulation of Age-related Decline by Transcription Factors and Their Crosstalk with the Epigenome.Current genomics · 2018Review
- mTOR signaling plays a critical role in the defects observed in muscle-derived stem/progenitor cells isolated from a murine model of accelerated aging.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2017Article
- Biomechanical Strain Exacerbates Inflammation on a Progeria-on-a-Chip Model.Small (Weinheim an der Bergstrasse, Germany) · 2017Article
- mTOR kinase inhibitor pp242 causes mitophagy terminated by apoptotic cell death in E1A-Ras transformed cells.Oncotarget · 2015Article
- The Intricate Interplay between Mechanisms Underlying Aging and Cancer.Aging and disease · 2015Review
- Article
- Article
- Oxidative stress and antioxidant response in fibroblasts from Werner and atypical Werner syndromes.Aging · 2014Article
- A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma.Oncotarget · 2014Article
- HP1α mediates defective heterochromatin repair and accelerates senescence in Zmpste24-deficient cells.Cell cycle (Georgetown, Tex.) · 2014Article
- Functional diversity and pharmacological profiles of the FKBPs and their complexes with small natural ligands.Cellular and molecular life sciences : CMLS · 2013Review
- Management of multicellular senescence and oxidative stress.Journal of cellular and molecular medicine · 2013Review
- Mechanisms of radiation toxicity in transformed and non-transformed cells.International journal of molecular sciences · 2013Review
- MTOR-driven quasi-programmed aging as a disposable soma theory: blind watchmaker vs. intelligent designer.Cell cycle (Georgetown, Tex.) · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A recent discovery that rapamycin suppresses a pro-senescent phenotype in progeric cells not only suggests a non-toxic therapy for progeria but also implies its similarity with normal aging. For one, rapamycin is also known to suppress aging of regular human cells. Here I discuss four potential scenarios, comparing progeria with both normal and accelerated aging. This reveals further indications of rapamycin both for accelerated aging in obese and for progeria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.